Inhibikase Therapeutics, Inc.
IKTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 13, 2026 | Chardan Capital | $1.50(-19%) | $1.84 | TheFly | |
| Jul 31, 2026 | H.C. Wainwright | Raghuram Selvaraju | $8.00(+251%) | $2.28 | StreetInsider |
| Jun 10, 2026 | Oppenheimer | $5.00(+199%) | $1.67 | TheFly | |
| Dec 11, 2025 | Cantor Fitzgerald | Olivia Brayer | $4.00(+167%) | $1.50 | TheFly |
| Nov 8, 2024 | Jefferies | Dennis Ding | $8.00(+188%) | $2.78 | StreetInsider |
| Oct 11, 2024 | H.C. Wainwright | Edward White | $5.00(+252%) | $1.42 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Neutral | Mar 28, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Feb 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 30, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 22, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 18, 2023 |
| JonesTrading | downgrade | Buy →Hold | Nov 16, 2022 |
| JonesTrading | maintain | Buy | Jul 15, 2021 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.11| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.11 | $-0.11 | — | — |
| May 12, 2026 | $-0.10 | $-0.10 | — | — |
| Mar 26, 2026 | $-0.09 | $-0.12 | — | — |
| Nov 14, 2025 | $-0.13 | $-0.13 | — | — |
| Aug 14, 2025 | $-0.11 | $-0.09 | — | — |
| May 14, 2025 | $-0.15 | $-0.11 | — | — |
| Mar 27, 2025 | $0.88 | $-0.10 | — | — |
| Nov 14, 2024 | $-0.65 | $-0.38 | — | — |
News
WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced that the Company's management will be participating in the following investor conferences during the month of November and December 2026.
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M.
WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company's common stock to two newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of September 30, 2026 (the “Effective Date”). The inducement grants were previously approved by th…
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Insider and Institutional Ownership 3.8% of Inhibikase Therapeutics shares
Eli Lilly and Company (NYSE: LLY - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership. Profitability This table compares Eli Lilly
WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.